Rising antiparasitic drug cost in U.S. leads to higher patient costs, decreased quality of care

(Burness) A new study finds that the increasingly high prices in the United States of the drugs used to treat three soil-transmitted helminth infections--hookworm, roundworm (ascariasis), and whipworm (trichuriasis)--is not only the major driver for the increase in costs to patients with either Medicaid or private insurance, but it also may have a damaging impact on the quality-of-care patients receive as clinicians shift their prescribing patterns to more affordable yet less-effective medicines covered by insurance.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news